Illumina buying Grail for $7.1 billion to bolster oncology research
… Illumina is investing in its oncology and genetic R&D pipeline with its acquisition of Grail …

$7.1 BILLION ACQUISITION: ILLUMINA ACQUIRING ONCOLOGY DIAGNOSTICS INNOVATOR GRAIL

Acquisition pairs Grail with one of its founding investor organizations and forms a cancer care genetics research leader

Illumina acquires Grail

Grail is backed by an array of prominent investors

As an innovator in oncology, Grail’s research is highly specialized

Illumina tackles advanced research in numerous sectors while generating significant sales

  • Agrigenomics
  • Cancer
  • Cellular and molecular biology
  • Complex diseases
  • Genetic and rare diseases
  • Microbiology
  • Reproductive health